Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Immunocore Q4 & Full Year 2025 Earnings Call - KIMMTRAK $400M, Phase 3 Readouts Point to a Make-or-Break 2H26
Immunocore closed 2025 on commercial strength, with KIMMTRAK delivering $400 million in net revenue, up 29% year-on-year, broader global rollout and real-world duration of therapy now 14 months. Manag...
- KIMMTRAK net revenue reached $400 million in 2025, a 29% increase versus 2024.
- KIMMTRAK is approved in 39 countries and launched in 30 markets, with real-world mean duration of therapy at 14 months.
- Real-world evidence presented at ESMO IO from 150 patients showed a median overall survival of 28 months; company will publish additional U.S. RWE and 5-year registrational OS data in 2026.
- +13 more takeaways
Geron Corporation Q4 2025 Earnings Call - RYTELO set to scale in 2026 with $220M-$240M guidance targeting ~8,000 second-line lower-risk MDS patients
Geron closed 2025 with a full commercial year behind RYTELO and is explicitly repositioning as a U.S.-focused hematology commercial story in 2026. Q4 net revenue was $48 million and full-year RYTELO s...
- RYTELO net revenue: Q4 2025 was $48 million; full-year 2025 RYTELO net revenue totaled $184 million (vs $76M in 2024).
- 2026 guidance: RYTELO net revenue of $220M to $240M; total operating expenses guided to $230M to $240M, implying roughly $20M YoY reduction at the midpoint. Management expects a back-half-weighted growth cadence in 2026.
- Commercial focus: Geron is prioritizing second-line, lower-risk MDS patients in the U.S., estimating an addressable population of approximately 8,000 patients. Second-line is the primary growth lever.
- +11 more takeaways
Amarin Corporation Q4 2025 Earnings Call - Recordati partnership and restructuring put company on cash-flow positive path
Amarin used 2025 to pivot from a standalone commercial model to a partnered international strategy and to slash costs, and the early results are tangible. The recordati licensing deal delivered $25 mi...
- Q4 2025 total net revenue was $49.2 million, down from $62.3 million year-over-year, driven by U.S. pricing declines and prior-year stocking in Rest of World markets.
- U.S. net sales declined 7% in Q4 due to lower net selling price; management expects the bulk of annual U.S. volume declines to occur in Q1 because of payer annual reset dynamics.
- Amarin says VASCEPA retains market leadership among all icosapent ethyl products in the U.S. five years after the first generic entry, and major managed care exclusives were maintained through 2025.
- +14 more takeaways
Dole plc Q4 and Full Year 2025 Earnings Call - $395M Adjusted EBITDA, Targeting at least $400M in 2026 Amid Fresh Fruit Cost Headwinds
Dole closed 2025 with resilient operating results and a clear pivot toward a simpler, more capital flexible company. Adjusted EBITDA for the year was $395 million, revenue rose to $9.2 billion, and ma...
- Adjusted EBITDA for full year 2025 was $395 million, coming in ahead of the company's latest guidance.
- Management is targeting at least $400 million of Adjusted EBITDA for 2026, with a caveat: early-year supply and cost headwinds may weight profits toward the back half of the year.
- Revenue for the year rose to $9.2 billion, an 8.2% increase year over year; Q4 revenue was $2.4 billion, up 9.2% reported and 5.7% like-for-like.
- +12 more takeaways
Diageo F26 Interim Earnings Call - Dividend cut to fund competitiveness and Guinness capacity
Diageo described the F26 interim results as mixed: strength in Latin America, Europe and Africa offset by notable weakness in Chinese white spirits and North America. Management reconfirmed near-term ...
- Results described as mixed: encouraging performance in Latin America, Europe and Africa, offset by weakness in Chinese white spirits and North America.
- Board revised dividend policy to a 30%–50% payout range to free up cash for reinvestment and faster balance sheet repair.
- Management reaffirmed commitment to generating ~3 billion of cash this year (figure referenced in the call).
- +12 more takeaways
HSBC Holdings PLC FY2025 Earnings Call - Hang Seng Privatization Unlocks Growth, Targets 17%+ RoTE and 5% Revenue by 2028
HSBC closed 2025 with a strong performance and a clear strategic pivot: deliver disciplined simplification, double down on customer-led growth, and redeploy capital into high-return markets. Results: ...
- FY2025 group revenues rose 5% on a constant currency basis, with profit before tax up 7% to a record $36.6 billion, excluding notable items.
- Return on tangible equity reached 17.2% for 2025, and management targets RoTE of 17% or better in each year from 2026 to 2028, excluding notable items.
- HSBC completed the $13.7 billion privatization of Hang Seng Bank on 26 January 2026, removing a $3.8 billion minority capital inefficiency and increasing balance sheet flexibility.
- +12 more takeaways
Haleon FY2025 Earnings Call - 3-5% Organic Growth Guide for 2026 Flags U.S. Recovery, But Cold and Flu Headwinds Persist
Haleon closed FY2025 with 3% organic sales growth, better margin performance, and a cautious outlook for 2026. Management guided 3% to 5% organic growth for 2026 while reiterating a medium-term ambiti...
- FY2025 organic sales growth was 3%, below prior internal expectations, with the U.S. down about 0.5% on a weak cold and flu season.
- Haleon guided 3% to 5% organic growth for 2026, while keeping a medium-term ambition of 4% to 6% and acknowledging current market uncertainty.
- Management expects the U.S. to return to growth in 2026, pointing to normalized inventories, commercial changes, and locked Q2 shelving resets that should increase distribution and shelf placement.
- +12 more takeaways
Xenia Hotels & Resorts, Inc. Q4 2025 Earnings Call - Scottsdale Ramp and Group Strength Drive FFO Growth
Xenia closed 2025 with better-than-expected operating performance, driven by a heavy lift from group demand and the commercial ramp of the transformed Grand Hyatt Scottsdale. Management booked double-...
- Adjusted FFO per share for full-year 2025 was $1.76, representing double-digit percentage growth versus 2024 and exceeding prior guidance.
- Q4 2025 net income was $6.1 million; Q4 Adjusted EBITDARE was $63.6 million and Q4 Adjusted FFO per share was $0.45, at or above the top end of implied guidance.
- Grand Hyatt Scottsdale completed a transformative renovation and materially ramped in 2025, contributing to a 104%+ RevPAR increase at that property year-over-year and underpinning 2026 expectations.
- +12 more takeaways
Westlake Chemical Partners Fourth Quarter and Full Year 2025 Earnings Call - Fixed‑margin ethylene deal keeps cash steady despite Petro 1 turnaround
Westlake Chemical Partners leaned on a long-standing fixed margin Ethylene Sales Agreement to deliver predictable cash flows through a year punctuated by a planned Petro 1 turnaround. Results show the...
- Fixed margin Ethylene Sales Agreement covers 95% of annual planned production and remains the core driver of predictable earnings and cash flow.
- OpCo renewed the Ethylene Sales Agreement with Westlake through 2027 with no changes to contract terms, underlining Westlake’s reliance on OpCo supply.
- Westlake Partners reported full year 2025 partnership net income of $49 million, or $1.38 per unit.
- +12 more takeaways
OMA Fourth Quarter 2025 Earnings Call - MXN 16 billion 2026-2030 MDP approved, improving capex-per-passenger as traffic recovers
OMA closed 2025 with a clean regulatory win and traffic momentum, and the story is efficiency rather than scale. Regulators approved a MXN 16 billion Master Development Program for 2026-2030, focused ...
- Regulatory win: Federal Civil Aviation Agency approved OMA's Master Development Program for 2026-2030, with an investment commitment of ~MXN 16 billion (expressed in Dec 2024 pesos).
- MDP focus: Capital allocated to terminal expansions, airside infrastructure, equipment upgrades, pavement rehabilitation, environmental and safety programs, plus tech to boost passenger experience and operational efficiency.
- Capex efficiency point: Management says the 2026-2030 program is comparable in real terms to 2021-2025 spending, but higher base traffic today implies better capex per passenger.
- +12 more takeaways